C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B
about
GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System FunctionRET/GFRα signals are dispensable for thymic T cell development in vivoGDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson diseaseDifferential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesisPositive selection for new disease mutations in the human germline: evidence from the heritable cancer syndrome multiple endocrine neoplasia type 2BThe candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing peripheral nerve dysfunctionMedullary thyroid cancer: monitoring and therapy.Neuropathology of paediatric chronic intestinal pseudo-obstruction and related animal models.A Drosophila model of multiple endocrine neoplasia type 2.A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-dSprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinomaGlial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence.Molecular genetics of multiple endocrine neoplasia types 1 and 2.Mouse models of thyroid cancer: A 2015 update.Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.Drosophila cancer models.Medullary thyroid carcinoma: a 25-year perspective.Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells.Thyroid C-Cell Biology and Oncogenic Transformation.Cellular and molecular events on the development of mammalian thyroid C cells.The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine.Malignant pheochromocytoma: state of the field with future projections.Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.Flanking regulatory sequences of the locus encoding the murine GDNF receptor, c-ret, directs lac Z (beta-galactosidase) expression in developing somatosensory system.Germline Stem Cell Competition, Mutation Hot Spots, Genetic Disorders, and Older Fathers.Multiple endocrine neoplasia 2B: Differential increase in enteric nerve subgroups in muscle and mucosa.Non-mammalian models of multiple endocrine neoplasia type 2.Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.Genomic organisation of the mouse Ret proto-oncogene.Constitutive Ret signaling leads to long-lasting expression of amphetamine-induced place conditioning via elevation of mesolimbic dopamine.
P2860
Q27309907-A8C51568-ECD6-4BA6-9D41-333D7D83A313Q27323436-ECAAD061-FEEE-4EC4-96C9-2BB831702CBDQ28083626-E76F151D-1BC0-42E6-A8B7-59C5ABDB5236Q28354358-C435E712-4F42-46D3-A212-B979890804DBQ28480870-DD2538FB-C34A-41D1-88C5-A7E1138ACAD3Q28591458-FCB6E8D8-72F0-4957-80C2-90EA1A5C17A0Q33591999-E511F25B-1C67-410F-80A1-3C6967002DB3Q34299988-02261C6B-BCA9-4F71-83AC-FC765FBCB825Q34589821-D360480E-E654-4A67-A2EB-ABDAFA491A47Q35083569-B3D5E104-E976-4CA2-8A93-628A6A7F269AQ36043347-7A8F4BA9-F5F4-4932-AD6F-2C6BA84DC531Q36074979-8015E6EA-D7D3-47E0-946F-676E5C0BE7DCQ36111935-C2457982-CB68-4E44-9378-DD2B6395F9A2Q36405539-9179633B-688D-4773-925B-F3F00487C3ACQ37613428-4F14F1BA-22DE-415C-B6AC-44E148E04D45Q37950977-0085ACA8-D414-4ED0-84CA-9A62C6C8A753Q38171726-3878A6BB-60D5-469A-9FB8-120E2784BDADQ38305599-9251B553-E0B1-49D9-AAF8-327F4F803C5EQ38614485-161060A7-F916-4BD8-9AFF-3CDCA5C20AABQ38667783-7F4F68F9-8205-41F7-B44F-1EC1D249840CQ38814755-7F4B1D0B-F8B2-4E55-B813-0BE200330DFDQ39029976-26EEA52A-B8E6-4149-BC08-55B623185BEDQ39298013-D55BF8BF-7A84-4996-A78A-8C9303CEEA32Q40016812-0B044989-FB6A-4B8B-B35E-99A5F67510F6Q40270415-DCED6A00-C4B3-435C-9EA1-F64E124502D6Q40277135-7C7DB836-20AF-4463-BDCA-305F7AC9027CQ40762789-2B5E2FB4-D33B-4C58-BBAB-B31FF14E8EB0Q40989489-8BD19113-5800-4E90-8786-8A3923225A0DQ41449967-26A29471-D166-44EB-8F80-17040A047D83Q47724734-E2F196C1-5B61-4F1C-8E00-AB291B42A0CEQ48266887-ADE51957-1CE9-44A5-BA41-ED9411474CC0Q48334451-2024A818-9780-4AC6-88C2-AEFDEDB589E3Q50069089-DF913450-A4C8-4916-B10E-922004E91425
P2860
C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@ast
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@en
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@nl
type
label
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@ast
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@en
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@nl
prefLabel
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@ast
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@en
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@nl
P2093
P2860
P356
P1433
P1476
C-cell hyperplasia, pheochromo ...... le endocrine neoplasia type 2B
@en
P2093
A S Tischler
C L Smith-Hicks
F Costantini
J F Powers
P2860
P304
P356
10.1093/EMBOJ/19.4.612
P407
P577
2000-02-01T00:00:00Z